Streamlining Beovu Denial Management with Klivira Automation
Effective Beovu denial management is critical for maintaining revenue integrity and ensuring timely patient access to essential anti-VEGF therapy. Klivira's automation platform streamlines the entire denial appeal process for specialty drugs like Beovu, from intake to resolution.
Denials for high-cost specialty medications, particularly those administered in-office like Beovu, present significant operational and financial challenges for revenue cycle teams. These often stem from complex payer policies, step-therapy requirements, or specific clinical documentation needs. Manual denial workflows lead to rework, missed timely-filing deadlines, and ultimately, lost revenue.
The Complexities of Beovu Denial Management
Beovu (brolucizumab) is a high-volume prior authorization target within the anti-VEGF class, frequently encountering denials across commercial, Medicare Advantage, and Medicaid managed care plans. Denials often arise from formulary restrictions, step-therapy prerequisites, or specific clinical necessity criteria, requiring meticulous documentation and timely appeals. Klivira addresses these specific challenges by automating the denial lifecycle.
Klivira's Automated Workflow for Beovu Denials
Klivira ingests Beovu-related denials from X12 835, X12 277, Da Vinci PAS ClaimResponse transactions, and payer portals. Our system normalizes X12 CARC/RARC codes and payer-specific variations, automatically categorizing denials for Beovu into appropriate appeal pathways: claim correction, clinical appeal, or peer-to-peer review. This ensures rapid, accurate triage for intravitreal injection therapies.
Addressing Common Beovu Denial Triggers
- Formulary Exclusions/Step Therapy: Automated generation of appeal letters detailing prior-line therapy failures or contraindications, referencing payer-specific medical policies.
- Clinical Necessity: FHIR-driven retrieval of specific clinical notes, imaging reports, and ophthalmologist attestations to support Beovu's medical necessity for wet AMD.
- Missing/Incorrect Documentation: Proactive identification and auto-assembly of all required documentation, including visual acuity measurements, OCT scans, and treatment history.
- Timely Filing: Automated tracking and enforcement of payer-specific appeal deadlines, preventing lost revenue due to administrative oversight.
- Site-of-Service Issues: Verification of appropriate billing codes and place-of-service modifiers for in-office administration of Beovu.
Precision Documentation for Beovu Appeal Packets
For Beovu clinical necessity denials, Klivira leverages EMR integration via FHIR to automatically discover and compile all relevant clinical documentation. This includes recent ophthalmology notes, visual acuity changes, OCT findings, and previous anti-VEGF treatment history, ensuring that every appeal packet is robust and aligned with payer medical policies for wet AMD.
Seamless Integration for Beovu Appeals
Klivira's platform supports appeal submission for Beovu through multiple channels, including direct payer portal APIs, secure fax, and Da Vinci PAS-conformant resubmission where applicable. This multi-channel approach ensures that appeals for this specialty drug, whether under medical or pharmacy benefit, are submitted efficiently and tracked with real-time status updates, reducing manual follow-up.
Continuous Improvement Through Denial Pattern Analysis
Klivira's reporting capabilities provide actionable insights into Beovu denial patterns by payer, specific denial reason, and provider. This feedback loop allows health systems to proactively refine their upstream prior authorization submission processes for anti-VEGF therapies, reducing future denials and improving first-pass approval rates for Beovu.
Frequently asked questions
How does Klivira specifically handle Beovu step-therapy denials?
Klivira's system is configured with payer-specific medical policies for Beovu. For step-therapy denials, it automatically identifies if required prior-line therapies were attempted and failed, or if contraindications exist, then generates appeal letters with supporting documentation pulled from the EMR via FHIR.
What type of clinical documentation does Klivira gather for Beovu appeals?
Klivira automatically retrieves comprehensive clinical documentation via FHIR from the EMR, including ophthalmologist notes, visual acuity measurements, OCT imaging reports, and the patient's history of response to other anti-VEGF treatments, all crucial for supporting Beovu's medical necessity.
Can Klivira track Beovu appeals submitted through specialty pharmacy portals?
Yes, Klivira integrates with various payer and specialty pharmacy portals to ingest denial statuses and track appeal progress for Beovu. This ensures timely follow-up and compliance with appeal windows, regardless of the initial submission channel.
How does Klivira help reduce future Beovu denials?
Klivira provides detailed analytics on Beovu denial patterns, highlighting common reasons by payer or provider. This data enables revenue cycle and clinical teams to refine their prior authorization submission strategies, addressing root causes and improving first-pass approval rates for anti-VEGF medications.
Does Klivira support peer-to-peer review scheduling for Beovu denials?
For high-acuity clinical necessity denials for Beovu that necessitate peer-to-peer review, Klivira routes scheduling requests to the ordering clinicians and tracks the scheduling status, streamlining the process for these critical discussions.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo